Anti-infective treatment in intensive care: The role of glycopeptides View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1994-11

AUTHORS

R. N. Grüneberg, A. P. R. Wilson

ABSTRACT

Antibiotics are used in 80% of patients in the ICU, encouraging nosocomial infections with resistant organisms. If the antibiotic susceptibilities of the pathogen are known, a narrow-spectrum antibiotic is preferable to preserve the patient's resistance to colonization. However, treatment is often empirical and broad-spectrum combinations are commonly used. Gram-positive bacteriaemia is associated with invasive monitoring or intravascular catheters. If the device cannot be removed easily, the glycopeptides are the only agents likely to be active against most strains of the commonest pathogen, the coagulase-negative staphylococcus. Long-stay patients are susceptible to infection with enterococci and methicillin-resistantStaphylococcus aureus, which are often resistant to all the usual agents other than glycopeptides. Vancomycin is long established, but is nephrotoxic, requires serum monitoring, must be administered as an infusion and can cause red man syndrome. Teicoplanin can be given as a single daily bolus without similar side-effects or monitoring. In deep-seated staphylococcal infection, the usual dose of teicoplanin is adequate if given in combination with other agents, but it may need to be doubled if used as monotherapy. Monitoring of the levels in the serum is helpful to ensure an adequate dose in patients with renal failure or in drug abusers, but is not needed to prevent toxicity. More... »

PAGES

s17-s22

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf01713978

DOI

http://dx.doi.org/10.1007/bf01713978

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1024211945

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/7699151


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Critical Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross Infection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Monitoring", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Microbial", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gram-Positive Bacterial Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Clinical Microbiology, University College Hospital, Grafton Way, WC1E 6AU, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.439749.4", 
          "name": [
            "Department of Clinical Microbiology, University College Hospital, Grafton Way, WC1E 6AU, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gr\u00fcneberg", 
        "givenName": "R. N.", 
        "id": "sg:person.01357430677.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357430677.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Microbiology, University College Hospital, Grafton Way, WC1E 6AU, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.439749.4", 
          "name": [
            "Department of Clinical Microbiology, University College Hospital, Grafton Way, WC1E 6AU, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wilson", 
        "givenName": "A. P. R.", 
        "id": "sg:person.012244705372.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012244705372.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf01739321", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014171318", 
          "https://doi.org/10.1007/bf01739321"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01645356", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010466776", 
          "https://doi.org/10.1007/bf01645356"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01656404", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022759305", 
          "https://doi.org/10.1007/bf01656404"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-199040030-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017750772", 
          "https://doi.org/10.2165/00003495-199040030-00007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00273537", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028162208", 
          "https://doi.org/10.1007/bf00273537"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01708581", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032284209", 
          "https://doi.org/10.1007/bf01708581"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1994-11", 
    "datePublishedReg": "1994-11-01", 
    "description": "Antibiotics are used in 80% of patients in the ICU, encouraging nosocomial infections with resistant organisms. If the antibiotic susceptibilities of the pathogen are known, a narrow-spectrum antibiotic is preferable to preserve the patient's resistance to colonization. However, treatment is often empirical and broad-spectrum combinations are commonly used. Gram-positive bacteriaemia is associated with invasive monitoring or intravascular catheters. If the device cannot be removed easily, the glycopeptides are the only agents likely to be active against most strains of the commonest pathogen, the coagulase-negative staphylococcus. Long-stay patients are susceptible to infection with enterococci and methicillin-resistantStaphylococcus aureus, which are often resistant to all the usual agents other than glycopeptides. Vancomycin is long established, but is nephrotoxic, requires serum monitoring, must be administered as an infusion and can cause red man syndrome. Teicoplanin can be given as a single daily bolus without similar side-effects or monitoring. In deep-seated staphylococcal infection, the usual dose of teicoplanin is adequate if given in combination with other agents, but it may need to be doubled if used as monotherapy. Monitoring of the levels in the serum is helpful to ensure an adequate dose in patients with renal failure or in drug abusers, but is not needed to prevent toxicity.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf01713978", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1313639", 
        "issn": [
          "0342-4642", 
          "1432-1238"
        ], 
        "name": "Intensive Care Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "keywords": [
      "long-stay patients", 
      "anti-infective treatment", 
      "role of glycopeptides", 
      "red man syndrome", 
      "narrow-spectrum antibiotics", 
      "methicillin-resistantStaphylococcus aureus", 
      "broad-spectrum combinations", 
      "coagulase-negative staphylococci", 
      "daily bolus", 
      "renal failure", 
      "man syndrome", 
      "usual dose", 
      "intensive care", 
      "adequate dose", 
      "staphylococcal infections", 
      "invasive monitoring", 
      "nosocomial infections", 
      "intravascular catheters", 
      "serum monitoring", 
      "common pathogens", 
      "resistant organisms", 
      "antibiotic susceptibility", 
      "drug abusers", 
      "patient resistance", 
      "only agent", 
      "patients", 
      "usual agents", 
      "infection", 
      "dose", 
      "teicoplanin", 
      "antibiotics", 
      "treatment", 
      "most strains", 
      "agents", 
      "monotherapy", 
      "ICU", 
      "bacteriaemia", 
      "catheter", 
      "pathogens", 
      "infusion", 
      "syndrome", 
      "bolus", 
      "vancomycin", 
      "nephrotoxic", 
      "serum", 
      "care", 
      "abusers", 
      "glycopeptides", 
      "staphylococci", 
      "monitoring", 
      "toxicity", 
      "aureus", 
      "enterococci", 
      "resistance", 
      "failure", 
      "susceptibility", 
      "combination", 
      "levels", 
      "role", 
      "colonization", 
      "strains", 
      "organisms", 
      "devices", 
      "Gram-positive bacteriaemia", 
      "single daily bolus"
    ], 
    "name": "Anti-infective treatment in intensive care: The role of glycopeptides", 
    "pagination": "s17-s22", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1024211945"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf01713978"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "7699151"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf01713978", 
      "https://app.dimensions.ai/details/publication/pub.1024211945"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_226.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf01713978"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf01713978'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf01713978'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf01713978'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf01713978'


 

This table displays all metadata directly associated to this object as RDF triples.

198 TRIPLES      22 PREDICATES      108 URIs      94 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf01713978 schema:about N007fe78a40114ac8857f609519017776
2 N18083d565d7f4afe936acde55e526f4f
3 N196e0de94bd84b81a684f6042cd5f99a
4 N1e2a88e37ebf4d6abdd1a1efaf474f77
5 N1e2cf9f901b149b9b83788f353bcfa3b
6 N43e296772262487fb8a04c9e7527112b
7 N4f3b851bcff04ed280189b9930fadca2
8 N764d41524709407ea647bc72dab5d5e7
9 N87ea79b6fc1f4d009defae3f9328e0ae
10 N9067a6f917c94c12b7eb4bbb74c74443
11 anzsrc-for:11
12 anzsrc-for:1103
13 schema:author Nba8960eb507347748663f2a9780bb649
14 schema:citation sg:pub.10.1007/bf00273537
15 sg:pub.10.1007/bf01645356
16 sg:pub.10.1007/bf01656404
17 sg:pub.10.1007/bf01708581
18 sg:pub.10.1007/bf01739321
19 sg:pub.10.2165/00003495-199040030-00007
20 schema:datePublished 1994-11
21 schema:datePublishedReg 1994-11-01
22 schema:description Antibiotics are used in 80% of patients in the ICU, encouraging nosocomial infections with resistant organisms. If the antibiotic susceptibilities of the pathogen are known, a narrow-spectrum antibiotic is preferable to preserve the patient's resistance to colonization. However, treatment is often empirical and broad-spectrum combinations are commonly used. Gram-positive bacteriaemia is associated with invasive monitoring or intravascular catheters. If the device cannot be removed easily, the glycopeptides are the only agents likely to be active against most strains of the commonest pathogen, the coagulase-negative staphylococcus. Long-stay patients are susceptible to infection with enterococci and methicillin-resistantStaphylococcus aureus, which are often resistant to all the usual agents other than glycopeptides. Vancomycin is long established, but is nephrotoxic, requires serum monitoring, must be administered as an infusion and can cause red man syndrome. Teicoplanin can be given as a single daily bolus without similar side-effects or monitoring. In deep-seated staphylococcal infection, the usual dose of teicoplanin is adequate if given in combination with other agents, but it may need to be doubled if used as monotherapy. Monitoring of the levels in the serum is helpful to ensure an adequate dose in patients with renal failure or in drug abusers, but is not needed to prevent toxicity.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree false
26 schema:isPartOf N4faaeaa5ef724389904925fed8b6a919
27 Nb1f086865f7841e39e27f7607433e105
28 sg:journal.1313639
29 schema:keywords Gram-positive bacteriaemia
30 ICU
31 abusers
32 adequate dose
33 agents
34 anti-infective treatment
35 antibiotic susceptibility
36 antibiotics
37 aureus
38 bacteriaemia
39 bolus
40 broad-spectrum combinations
41 care
42 catheter
43 coagulase-negative staphylococci
44 colonization
45 combination
46 common pathogens
47 daily bolus
48 devices
49 dose
50 drug abusers
51 enterococci
52 failure
53 glycopeptides
54 infection
55 infusion
56 intensive care
57 intravascular catheters
58 invasive monitoring
59 levels
60 long-stay patients
61 man syndrome
62 methicillin-resistantStaphylococcus aureus
63 monitoring
64 monotherapy
65 most strains
66 narrow-spectrum antibiotics
67 nephrotoxic
68 nosocomial infections
69 only agent
70 organisms
71 pathogens
72 patient resistance
73 patients
74 red man syndrome
75 renal failure
76 resistance
77 resistant organisms
78 role
79 role of glycopeptides
80 serum
81 serum monitoring
82 single daily bolus
83 staphylococcal infections
84 staphylococci
85 strains
86 susceptibility
87 syndrome
88 teicoplanin
89 toxicity
90 treatment
91 usual agents
92 usual dose
93 vancomycin
94 schema:name Anti-infective treatment in intensive care: The role of glycopeptides
95 schema:pagination s17-s22
96 schema:productId N441e2c7be96349ceb1a7c0a04fcad05e
97 N687ba4bd5c4443d8b5fee66c7b63f455
98 Nc2c2885d87624d53af57e7f3113510ce
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024211945
100 https://doi.org/10.1007/bf01713978
101 schema:sdDatePublished 2022-01-01T18:05
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher N3f29b5640c2644b7ba1d50a14f1d3764
104 schema:url https://doi.org/10.1007/bf01713978
105 sgo:license sg:explorer/license/
106 sgo:sdDataset articles
107 rdf:type schema:ScholarlyArticle
108 N007fe78a40114ac8857f609519017776 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Gram-Positive Bacterial Infections
110 rdf:type schema:DefinedTerm
111 N18083d565d7f4afe936acde55e526f4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Anti-Bacterial Agents
113 rdf:type schema:DefinedTerm
114 N196e0de94bd84b81a684f6042cd5f99a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Humans
116 rdf:type schema:DefinedTerm
117 N1e2a88e37ebf4d6abdd1a1efaf474f77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Glycopeptides
119 rdf:type schema:DefinedTerm
120 N1e2cf9f901b149b9b83788f353bcfa3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Clinical Trials as Topic
122 rdf:type schema:DefinedTerm
123 N3f29b5640c2644b7ba1d50a14f1d3764 schema:name Springer Nature - SN SciGraph project
124 rdf:type schema:Organization
125 N43e296772262487fb8a04c9e7527112b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Drug Resistance, Microbial
127 rdf:type schema:DefinedTerm
128 N441e2c7be96349ceb1a7c0a04fcad05e schema:name pubmed_id
129 schema:value 7699151
130 rdf:type schema:PropertyValue
131 N4f3b851bcff04ed280189b9930fadca2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Cross Infection
133 rdf:type schema:DefinedTerm
134 N4faaeaa5ef724389904925fed8b6a919 schema:issueNumber Suppl 4
135 rdf:type schema:PublicationIssue
136 N687ba4bd5c4443d8b5fee66c7b63f455 schema:name doi
137 schema:value 10.1007/bf01713978
138 rdf:type schema:PropertyValue
139 N764d41524709407ea647bc72dab5d5e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Drug Monitoring
141 rdf:type schema:DefinedTerm
142 N87ea79b6fc1f4d009defae3f9328e0ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Risk Factors
144 rdf:type schema:DefinedTerm
145 N9067a6f917c94c12b7eb4bbb74c74443 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Critical Care
147 rdf:type schema:DefinedTerm
148 Nb1f086865f7841e39e27f7607433e105 schema:volumeNumber 20
149 rdf:type schema:PublicationVolume
150 Nba8960eb507347748663f2a9780bb649 rdf:first sg:person.01357430677.71
151 rdf:rest Ne2e2fd5e1ba6488dabd3a594b05a819c
152 Nc2c2885d87624d53af57e7f3113510ce schema:name dimensions_id
153 schema:value pub.1024211945
154 rdf:type schema:PropertyValue
155 Ne2e2fd5e1ba6488dabd3a594b05a819c rdf:first sg:person.012244705372.25
156 rdf:rest rdf:nil
157 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
158 schema:name Medical and Health Sciences
159 rdf:type schema:DefinedTerm
160 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
161 schema:name Clinical Sciences
162 rdf:type schema:DefinedTerm
163 sg:journal.1313639 schema:issn 0342-4642
164 1432-1238
165 schema:name Intensive Care Medicine
166 schema:publisher Springer Nature
167 rdf:type schema:Periodical
168 sg:person.012244705372.25 schema:affiliation grid-institutes:grid.439749.4
169 schema:familyName Wilson
170 schema:givenName A. P. R.
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012244705372.25
172 rdf:type schema:Person
173 sg:person.01357430677.71 schema:affiliation grid-institutes:grid.439749.4
174 schema:familyName Grüneberg
175 schema:givenName R. N.
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357430677.71
177 rdf:type schema:Person
178 sg:pub.10.1007/bf00273537 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028162208
179 https://doi.org/10.1007/bf00273537
180 rdf:type schema:CreativeWork
181 sg:pub.10.1007/bf01645356 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010466776
182 https://doi.org/10.1007/bf01645356
183 rdf:type schema:CreativeWork
184 sg:pub.10.1007/bf01656404 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022759305
185 https://doi.org/10.1007/bf01656404
186 rdf:type schema:CreativeWork
187 sg:pub.10.1007/bf01708581 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032284209
188 https://doi.org/10.1007/bf01708581
189 rdf:type schema:CreativeWork
190 sg:pub.10.1007/bf01739321 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014171318
191 https://doi.org/10.1007/bf01739321
192 rdf:type schema:CreativeWork
193 sg:pub.10.2165/00003495-199040030-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017750772
194 https://doi.org/10.2165/00003495-199040030-00007
195 rdf:type schema:CreativeWork
196 grid-institutes:grid.439749.4 schema:alternateName Department of Clinical Microbiology, University College Hospital, Grafton Way, WC1E 6AU, London, UK
197 schema:name Department of Clinical Microbiology, University College Hospital, Grafton Way, WC1E 6AU, London, UK
198 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...